Video

Peter Chin, MD

Publish date: February 23, 2016

At the ACTRIMS 2016 Forum, Dr. Chin discussed top-line results from the ORATORIO trial of ocrelizumab in patients with primary progressive MS and also results of a subgroup analysis of patients with gad-enhancing lesions at baseline.

 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Meningeal B-Cell Infiltrates May Cause Cortical Injury in Progressive MS
ICYMI Multiple Sclerosis
Immunomodulatory Therapy Slows Accumulation of Disability in Moderately Advanced MS
ICYMI Multiple Sclerosis
Exercise May Improve Inhibitory Control in MS
ICYMI Multiple Sclerosis
Levels of Immune Cells Do Not Differ Between Relapsing-Remitting and Progressive MS
ICYMI Multiple Sclerosis
VIDEO: ACTRIMS Forum focuses on progressive MS
ICYMI Multiple Sclerosis
ACTRIMS: Treadmill exercise transiently benefits cognition in MS patients
ICYMI Multiple Sclerosis
ACTRIMS: Ovarian decline linked to MS progression in women
ICYMI Multiple Sclerosis
Ovarian Decline May Be Associated With Disability in Women With MS
ICYMI Multiple Sclerosis
Does Fatigue Worsen Spasticity in Patients With MS?
ICYMI Multiple Sclerosis
VIDEO: Bench research provides insight into progressive MS
ICYMI Multiple Sclerosis